Enanta Pharmaceuticals, Inc.
ENTA
$11.34
-$0.01-0.09%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.19% | 46.44% | 35.12% | 19.43% | 27.32% |
| Total Depreciation and Amortization | 0.50% | 38.36% | 168.06% | 103.70% | 93.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.28% | -57.86% | -36.87% | -51.04% | 10.62% |
| Change in Net Operating Assets | -102.32% | -2,650.44% | -41.25% | 1,098.59% | 163.04% |
| Cash from Operations | 46.95% | 30.37% | 37.61% | 218.48% | 52.84% |
| Capital Expenditure | 99.41% | 98.36% | 83.71% | 97.63% | -52.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 753.03% | -160.73% | -86.60% | -13,464.47% | -103.04% |
| Cash from Investing | 373.33% | -168.64% | -87.96% | -317.38% | -107.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 79,571.28% | -25.00% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.64% | -111.71% | -14.95% | 3.76% | -6.53% |
| Cash from Financing | -5.92% | 1,386.32% | -15.33% | 3.35% | -7.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.86% | -89.09% | -958.30% | 44.53% | -204.81% |